ALK and non-small cell lung carcinoma: At the time of the first trial report, 14 patients with ALK+ NSCLC had been enrolled, and the preliminary findings showed that 4/14 (28.5%) of the refractory patients had attained a PR and a patient harboring the G1202R mutation had attained a minimal response (<30%).